Abstract:ID 92941 Poster Board 546 Ebola virus (EBOV), a negative-sense RNA virus, is zoonotic pathogen that causes severe hemorrhagic fever with high case fatality rates in humans. EBOV disease outbreaks have been occurring since 1976. The largest outbreaks took place in West African in 2014 and resulted in over 28,000 cases and 11,000 deaths. There have been advances in the development of EBOV vaccines and monoclonal antibodies. However, no antiviral drugs are yet approved, especially for the treatment of pan-filovirus infections. EBOV transcription requires viral VP30 and VP35 proteins, which, according to our recently conducted global proteomic study (1), are phosphorylated in the EBOV virions. Phosphorylation of VP35 on Thr-210 regulated EBOV transcriptional activity and VP35 interaction with EBOV-NP (1). Host protein phosphatases, PP1 and PP2A were shown to facilitate EBOV transcription and replication (2,3). Our unpublished observations indicate that NP E619K mutant binds stronger to PP1 and that binding compromises formation of EBOV capsid. Thus, targeting PP1 might be a valuable approach for EBOV inhibition. Recent high throughout screen conducted in Mathieu Bollen's laboratory at KULeuven identified several gold-containing compounds including FDA approved Auranofin among 400,000 compounds that were screened for PP1 as target. Here we tested the effect of Auranofin and chloro-gold compounds on EBOV transcription and replication and NP interaction with VP35. Auranofin inhibited EBOV minigenome (IC 50 = 0.5 μM) and also potently inhibited EBOV and MARV replication in Vero E6 cells at submicromolar concentrations. Compared to chloro-gold compound, Auranofin showed at least 10-times better efficacy and also less toxicity. To determine the mechanism of Auranofin action, we investigated its effect on the NP-VP35 and NP-NP interactions using split NanoBiT assay. Auranofin potently inhibited NP binding to VP35 in split NanoBiT (IC 50 = 3 μM) comparing to chloro-gold (IC 50 = 12 μM). Auranofin demonstrated low cytotoxicity (IC 50 >300 μM) in 293T cells that were used for the split NanoBiT. Auranofin also showed potent inhibition of NP-NP interaction in split NanoBiT (IC 50 = 1 μM) comparing to chloro-gold (IC 50 = 3 μM). Taken together, our study suggests that Auranofin may serve as EBOV inhibitor by targeting EBOV NP-VP35 and NP-NP interactions. As Auranofin is approved for human use for rheumatoid arthritis, it is feasibly can be further tested as an inhibitor for EBOV and MARV infections References Ivanov A, ... Bukreyev A, Nekhai S. 2020. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cell Mol Life Sci 77:2579–2603. Ilinykh PA, ... Nekhai S, Bukreyev A. 2014. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723–38. Kruse T, ... Nilsson J, Becker S. 2018. The Ebola Virus Nucleoprotein Recruits the Host PP2A-B56 Phosphatase to Activate Transcriptional Support Activity of VP30. Mol Cell 69:136–145 e6 Acknowledgements: We thank Dr. Mathieu Bollen for sharing screening data, Dr. Elke Mühlberger for providing the EBOV minigenome, and Dr. Yoshihiro Kawaoka for providing the plasmids expressing EBOV NP, VP35, L, VP30, and the T7 polymerase. This project was supported by the NIH Research Grants U19AI109664, 5U54MD007597, 2R01HL125005 and P30AI117970

Selective Inhibitor of Nuclear Export (SINE) Compounds Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian Cells

Competitive Binding of Viral Nuclear Localization Signal Peptide and Inhibitor Ligands to Importin-α Nuclear Transport Protein

Binding of Inhibitors to Nuclear Localization Signal Peptide from Venezuelan Equine Encephalitis Virus Capsid Protein Explored with All-Atom Replica Exchange Molecular Dynamics

In Silico Screening of Inhibitors of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease

Identification of Quinolinones As Antivirals Against Venezuelan Equine Encephalitis Virus.

TRIM32 inhibits Venezuelan Equine Encephalitis Virus Infection by targeting a late step in viral entry

Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection

Engineered External Guide Sequences Effectively Block Viral Gene Expression and Replication in Cultured Cells

RNA structures within Venezuelan equine encephalitis virus E1 alter macrophage replication fitness and contribute to viral emergence

Ribonuclease P-mediated inhibition of human cytomegalovirus gene expression and replication induced by engineered external guide sequences.

Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses

Mechanisms of anti-vesicular stomatitis virus activity of deazaneplanocin and its 3-brominated analogs

Auranofin Inhibits Ebola Virus Replication by Targeting NP-VP35 and NP-NP Interactions

Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

Eukaryotic translation elongation factor 1 alpha (eEF1A) inhibits Siniperca chuatsi rhabdovirus (SCRV) infection through two distinct mechanisms

Two novel compounds inhibit Flavivirus infection in vitro and in vivo by targeting lipid metabolism

1-Formyl-β-carboline Derivatives Block Newcastle Disease Virus Proliferation through Suppressing Viral Adsorption and Entry Processes

Inhibiting the transcription and replication of Ebola viruses by disrupting the nucleoprotein and VP30 protein interaction with small molecules

Interferon inhibits a model RNA virus via a limited set of inducible effector genes

Inhibition of Chikungunya virus by an adenosine analog targeting the SAM‐dependent nsP1 methyltransferase